Found: 14
Select item for more details and to access through your institution.
A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-06451-w
- By:
- Publication type:
- Article
Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
- Published in:
- 2019
- By:
- Publication type:
- Correction Notice
Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 175, n. 2, p. 339, doi. 10.1007/s10549-019-05166-3
- By:
- Publication type:
- Article
Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-23793-7
- By:
- Publication type:
- Article
Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells.
- Published in:
- Clinical & Experimental Metastasis, 2002, v. 19, n. 7, p. 603, doi. 10.1023/A:1020950420196
- By:
- Publication type:
- Article
A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
- Published in:
- Breast Cancer Research & Treatment, 2014, v. 146, n. 2, p. 259, doi. 10.1007/s10549-014-3014-7
- By:
- Publication type:
- Article
Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research.
- Published in:
- PLoS ONE, 2020, v. 15, n. 4, p. 1, doi. 10.1371/journal.pone.0231953
- By:
- Publication type:
- Article
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1α protein-dependent mechanism.
- Published in:
- International Journal of Cancer, 2011, v. 128, n. 10, p. 2306, doi. 10.1002/ijc.25589
- By:
- Publication type:
- Article
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2024, v. 43, n. 1, p. 1, doi. 10.1186/s13046-024-03143-3
- By:
- Publication type:
- Article
Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines.
- Published in:
- Biomedicines, 2023, v. 11, n. 3, p. 735, doi. 10.3390/biomedicines11030735
- By:
- Publication type:
- Article
ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells.
- Published in:
- Biomedicines, 2021, v. 9, n. 10, p. 1410, doi. 10.3390/biomedicines9101410
- By:
- Publication type:
- Article
PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening.
- Published in:
- Biomedicines, 2021, v. 9, n. 7, p. 740, doi. 10.3390/biomedicines9070740
- By:
- Publication type:
- Article
Cdc42 and Rac1 are necessary for autotaxin-induced tumor cell motility in A2058 melanoma cells
- Published in:
- FEBS Letters, 2002, v. 532, n. 3, p. 351, doi. 10.1016/S0014-5793(02)03698-0
- By:
- Publication type:
- Article